Scientists Perform First Comprehensive Sequencing of Mantle Cell Lymphomas

Scientists have undertaken the first truly comprehensive analysis of mantle cell lymphoma (MCL).

Scientists led by Xose S. Puente and Carlos López Otín from the University of Oviedo, and researchers Sílvia Beà and Elías Campo, from the Faculty of Medicine of the UB, IDIBAPS and the Hospital Clínic of Barcelona have published the sequenced genomes of more than 30 mantle cell lymphomas in the journal Proceedings of the National Academy of Sciences (PNAS).

Examining samples for genetic changes

Said co-author Dr. Sílvia Beà:

The study provides insight into causes and evolution of this complex neoplasm and has identified targets for new treatments.

Their samples included early-stage tumors as well as advanced-stage tumors, a range which allowed them to identify genetic changes linked to this lymphoma subtype. They were also able to find genes that participate in the progression of MCL as well as mechanisms that cause treatment resistance.

Patients with MCL either have an aggressive form of the disease or a slow-growing form, and typically doctors don't know which one the patient has until they can see through scans and other data whether or not the disease is growing quickly.

But this research has genetic mutations believed to be associated with the more aggressive form, as well as mutations associated with the non-aggressive form.

This is the kind of finding that could lead to much quicker and smarter initial treatment decisions by doctors for their patients.

Source: University of Barcelona

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap